NL-OMON48424
Completed
Not Applicable
A two-part parallel group study to assess the safety, tolerability and pharmacokinetic (PK) profile of multiple oral doses of RDN-929 in healthy older adults and subjects with early symptomatic Alzheimer*s Disease - RDN-929-103 (CS0317)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Alzheimer's Disease
- Sponsor
- Rodin Therapeutics, Inc.
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Trial ended prematurely
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult males or postmenopausal or surgically sterile females age 55 \* 85 years
- •old for Part 1 and age 50\-85 years old for Part 2, inclusive, at the time of
- •informed consent.
- •Body mass index (BMI) \*18\.0 kg/m2, \<35\.0 kg/m2\.
- •Further inclusion criteria can be found in the protocol section 8\.5\.1\.
Exclusion Criteria
- •History or current evidence of any clinically significant cardiovascular,
- •endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic,
- •pulmonary, neurologic (except for diagnosis of AD in Part 2\), renal, or other
- •major disease, as determined by the Investigator.
- •Any conditions that, in the opinion of the Investigator, would make the subject
- •unsuitable for enrollment or could interfere with the subject\*s participation
- •in or completion of the study.
- •Further exclusion criteria can be found in the protocol section 8\.5\.2
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndromeNL-OMON48225Millendo Therapeutics SAS23
Completed
Phase 2
A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)Rheumatoid Arthritis10023213NL-OMON47882Astra Zeneca26
Completed
Phase 2
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta ThalassemiaBeta Thalassemiainherited blood disorder10038158NL-OMON54921IMARA, Inc.15
Completed
Not Applicable
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignanciesbeenmergstoornis: MDS (myelodysplastisch syndroom/myelodysplasie)Acute myeloid leukemiacancer of the bloodmyelodysplastic Syndrome10024324NL-OMON55859Amgen10
Completed
Phase 2
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutaneous Coronary InterventioNL-OMON51876Arena Pharmaceuticals, Inc.27